Celldex Therapeutics, Inc.

NasdaqCM:CLDX Stock Report

Market Cap: US$1.7b

Celldex Therapeutics Past Earnings Performance

Past criteria checks 0/6

Celldex Therapeutics's earnings have been declining at an average annual rate of -26.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 5.9% per year.

Key information

-26.1%

Earnings growth rate

1.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate5.9%
Return on equity-19.6%
Net Margin-1,544.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21
An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Sep 07
We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Jul 21

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Jul 14

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Revenue & Expenses Breakdown

How Celldex Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CLDX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2410-154370
30 Jun 248-1503515
31 Mar 246-145330
31 Dec 237-141310
30 Sep 234-125290
30 Jun 233-1132748
31 Mar 233-119270
31 Dec 222-112270
30 Sep 221-106270
30 Jun 221-100260
31 Mar 224-77230
31 Dec 215-71200
30 Sep 218-72180
30 Jun 219-66160
31 Mar 215-64150
31 Dec 207-60140
30 Sep 205-48140
30 Jun 204-46140
31 Mar 205-46140
31 Dec 194-51150
30 Sep 194-50170
30 Jun 195-46170
31 Mar 197-50190
31 Dec 1810-151190
30 Sep 1811-146210
30 Jun 1814-165220
31 Mar 1815-177230
31 Dec 1713-93250
30 Sep 1711-121270
30 Jun 179-125290
31 Mar 177-128300
31 Dec 167-129340
30 Sep 167-129350
30 Jun 166-131370
31 Mar 166-132370
31 Dec 155-127340
30 Sep 155-126290
30 Jun 155-122260
31 Mar 154-118220
31 Dec 144-118210
30 Sep 143-108190
30 Jun 143-103180
31 Mar 142-94160
31 Dec 134-82150

Quality Earnings: CLDX is currently unprofitable.

Growing Profit Margin: CLDX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CLDX is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.

Accelerating Growth: Unable to compare CLDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: CLDX has a negative Return on Equity (-19.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 19:23
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Celldex Therapeutics, Inc. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason WittesAegis Capital Corporation
Jonathan AschoffBrean Capital
Kristen KluskaCantor Fitzgerald & Co.